Positive five-year data, demonstrates the durability of fostemsavir

HIV specialist company ViiV Healthcare today announced week 240 results from the Phase III BRIGHTE study of Rukobia (fostemsavir) in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection who have very few treatment options left available to them due to resistance, intolerance, or other safety concerns. ViiV is majority-owned by UK pharma major GSK (LSE: GSK).

The BRIGHTE study is an international, two-cohort (randomized and non-randomized), Phase III clinical trial evaluating the safety and efficacy of fostemsavir, a first-in-class attachment inhibitor, used in combination with optimized background treatment (OBT) in 371 patients from 113 sites across 22 countries. Study findings showed that people living with multidrug-resistant HIV-1 treated for approximately five years with fostemsavir-based regimens experienced durable virologic responses and continued clinically meaningful improvements in CD4+ cell count and CD4+/CD8+ ratio. These findings were shared today during the 24th International AIDS Conference (AIDS 2022) in Montreal, Canada.

Fostemsavir is the only treatment available for this specific population